Delivery of therapeutic moieties to specific cell types, such as neurons remains a 25 challenge. Genes present in neurons are also expressed in non-neuronal cell types such as glia 26 where they mediate non-targeted related functions. Thus, non-specific targeting of these 27 proteins/channels has numerous unwanted side effects, as is the case with current small 28 molecules or drug therapies. Current methodologies that use nanoparticles, lipid-mediated uptake, 29 or mannitol in conjunction with lipids to deliver double-stranded RNA (dsRNA) have yielded 30 mixed and unreliable results. We used a neuroanatomical tracer (B subunit of Cholera Toxin 31 (CTB)) that binds to the ganglioside receptors (GM1) expressed on cells, including primary 32 sensory neurons to deliver encapsulated dsRNA. This approach greatly improved delivery of 33 dsRNA to the desired cells by enhancing uptake, reducing vehicle-mediated toxicity and 34 protecting nucleotides from degradation by endonucleases. The delivery complex is internalized, 35 and once inside the cell, the dsRNA naturally dissociates itself from the carrier complex and is 36 very effective in knocking down cognate targets, both in vivo and in vitro. Past methods have 37 used CTB-fusion proteins or chemically modified oligos or DNA moieties that have been 38 covalently conjugated to CTB. Furthermore, CTB conjugated to an antigen, protein, or 39 chemically modified nucleic acid is a potent activator of immune cell (T and B cells, 40 macrophages) response, whereas CTB admixed with antigens or unmodified nucleic acids does 41 not evoke this immune response. Importantly, in our method, the nucleic acids are not covalently 42 linked to the carrier molecules. Thus, our method holds strong potential for targeted delivery of 43 therapeutic moieties for cell types expressing GM1 receptors, including neuronal cell types.
Introduction

47
Targeted delivery of a therapeutic molecule to specific cells is highly desirable due to the 48 associated advantages. For example, the targeted delivery of the therapeutic molecule might 49 reduce systemic side effects resulting from off target effect of the therapeutic molecule as well as 50 immune response to the therapeutic molecule. Additionally, if a therapeutic molecule can be 51 targeted to a particular cell where the activity of the therapeutic molecule is needed, a lower 52 amount of the therapeutic molecule could be used, thereby lowering the cost of the treatment.
54
Although other methods for targeted delivery of therapeutic molecules have been 55 proposed [1], there is still a need for specific complexes that provide effective delivery of the 56 therapeutic molecule. The lack of methods for targeted delivery of nucleic acids in vitro and in 57 vivo is a limiting factor in the development of localized treatment. 177 native polyacrylamide gel by electrophoresis ( Fig. 2A) . In the second step of this reaction, we 225 of CQ in culture medium resulted in uptake of CTB by Neuro2A cells, but did not affect NR2B
226 expression, suggesting that CTB-PEG meleimide by itself does not alter expression of proteins.
227 Scale bar: 50µm. 231 of neurons, we should expect knockdown of NR2B in those subsets of neurons that take up CQ 232 complex. Cells were incubated with CQ-dsNR2B complex for 7-24 hours, and then transferred 233 to normal culture medium without CQ-dsNR2B. Seven hours after incubation with CQ-dsNR2B, 234 uptake was evident, but no knockdown of NR2B immunoreactivity was evident at this short time 235 point (Fig. 5A ). Two days after incubation with CQ-dsNR2B complex, Neuro2A cells showed 236 knockdown of NR2B in all cells that were positive for CTB immunoreactivity (Fig. 5B) . In cells 237 that did not take up CQ-dsNR2B, immunoreactive NR2B was clearly visible (Fig. 5B merge) . 243 showed expression of CTB and markedly reduced expression of NR2B-IR, whereas cells that did 244 not contain CTB showed robust NR2B-IR. Scale bar: 50µm 245 246 Discussion Here we show that the non-toxin subunit B of Cholera toxin, CTB that is routinely used 248 as a neuroanatomical tracer can be used to deliver potentially therapeutic moieties to sub-249 populations of neurons. Given the selective uptake of CTB-dsRNA complex in cultured cells, 250 this method has the potential to be a powerful way to study gene expression and cell signaling in 251 a subpopulation of neurons, even in a mixed population of cells, and in their natural milieu.
252 Currently, no such technique is available with this capacity. 260 Plasmid DNA has also been conjugated to  opioid receptor-liposome complexes for cell-261 specific delivery, but as is becoming apparent, chemical modification or fusion bacterial-262 mammalian proteins are immunogenic, and none of these methods can deliver unmodified 263 nucleic acids or proteins.
265
Although here we focused on CTB as the carrier molecule, our method potentially allows 266 us to encapsulate our resultant dsRNA/DNA nanoparticles with other carrier molecules such as 267 isolectin B4 (IB4). IB4 is also used as a neuroanatomical tracer and targets a different population 268 of neurons other than CTB. Potentially, IB4 and CTB can also be used in combination as carrier 269 molecules to increase targeted populations of neurons. Consequently, our method has wide 270 therapeutic potential.
272
The therapeutic areas that can be targeted with this delivery method could include any 
